Three short videos that detail new treatments and advances made against Myeloma.

[url]http://www.oncologytube.com/v/1037440/update-on-eloquent-2-phase-3-trial-of-elotuzumab-in-relapsed-refractory-multiple-myeloma[/url]

[url]http://www.oncologytube.com/v/1037456/transplant-vs-bortezomib-and-len-dex-in-multiple-myeloma[/url]

[url]http://www.oncologytube.com/v/1037462/remission-of-multiple-myeloma-with-car-t-cell-therapy[/url]

Of interest in high-risk refractory/relapsed cases is the effectiveness of Chimeric Antigen Receptor T-Cells (CAR-T). The problem seems to be one of dosage or possibly the via of administration, as the CAR-T Cells do provoke a rather serious immune response in the patient. They are also moving toward transplanting early on, which is another consideration.